1. Introduction {#sec1}
===============

Excess body weight affects 1.6 billion individuals globally \[[@B1]\], is associated with substantial premature morbidity and mortality \[[@B2], [@B3]\], impairs quality of life \[[@B4]\], and accounts for 2%--7% of direct healthcare spending in developed nations \[[@B5]\]. Sixty-six % and 60% of the adult population in the US and Canada, respectively, are overweight (body mass index (BMI) ≥ 25 kg/m^2^) or obese (BMI ≥ 30 kg/m^2^) \[[@B6], [@B7]\].

Despite the increasing recognition of obesity as a public health problem and the well-documented benefits of even modest weight loss on comorbidities \[[@B7]\], there is concern that obesity is underreported and undertreated by healthcare professionals. Although weight loss counseling increases the likelihood of attempted weight loss by 3-fold \[[@B8]\], only 43% of obese participants in a nationally representative survey of US adults reported receiving this intervention during their annual checkup \[[@B9]\]. At odds with patient perceptions is the finding that 75% of physicians report "always" or "nearly always" administering weight management counseling to their overweight or obese patients \[[@B10]\].

It also appears that, even among physicians who are providing weight management counseling to their patients, additional treatment options such as pharmacotherapy or referral to an additional program or provider are often not used \[[@B10], [@B11]\]. Weight management strategies such as expert-led diet and exercise counseling, commercial weight loss programs, pharmacotherapy, and behavioural therapy are recommended by current guidelines \[[@B7]\], and each can reduce weight by a clinically significant amount (at least 3%--5% of initial weight), which is associated with improvements in cardiovascular risk factors \[[@B12]--[@B15]\]. A recent study reported the following rates of referral/use: dietician (67%), commercial weight loss program (59%), exercise specialist (34%), and pharmacotherapy (29%) \[[@B10]\]. In a survey of 18 primary care practices in the US, only 14% of overweight or obese patients received a referral for further weight management \[[@B16]\].

Prior studies in this area have been retrospective in nature and thus potentially subject to recall bias \[[@B10], [@B16]\]. They have also not attempted to examine underlying reasons why physicians are not using these antiobesity management strategies. This report details the major findings of the State of Obesity Care in Canada Evaluation Registry (SOCCER) study, which was designed to examine in closer detail Canadian physicians\' use of antiobesity pharmacotherapy and referral patterns to additional obesity management programs and providers.

2. Methods {#sec2}
==========

2.1. Participating Practices and Patient Recruitment {#sec2.1}
----------------------------------------------------

Registration in a provincial registry is a mandatory requirement for all practicing physicians in Canada. Accordingly, provincial medical registries were used to identify all primary care and specialist physicians across Canada in 2005--2007. Approximately 2000 physicians were contacted by phone, fax and/or E-mail, and the 50 physicians across 45 medical practices that agreed to participate were sent study materials, including the study protocol, case report forms, and enrolment logs. Physicians received telephone instructions describing the proper procedure for recruiting patients and populating study forms. This included reading through the entire study form with the physician to ensure that accurate information was collected for each question. No specific instructions or education regarding weight management practices were provided to the physicians. Thirty-six physicians from 33 of the 45 sites (27 primary care and 6 specialist practices) recruited participants. The specialist practices consisted of endocrinologists, cardiologists, and/or general internists (who provide consultative specialty care within the Canadian health care system rather than primary care).

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Consecutive patients ≥ 18 years with BMI levels ≥ 27 kg/m^2^ who were able to provide informed consent were eligible for inclusion. A BMI threshold of 27 kg/m^2^ was chosen instead of 25 kg/m^2^ to increase the likelihood that patients were truly overweight (because BMI is an indirect measure of body fat) and because this cutoff is congruent with current recommendations for initiating drug therapy \[[@B7]\]. Patients were also required to have at least one indication for weight management, as judged by their physician.

Consecutive subjects seen during routine clinic operation and identified on predefined recruitment days were asked to participate. A patient could only be enrolled once in the study. Patients that were already participating in a clinical trial, hospitalized, pregnant, nursing, or unable to attend followup visits were excluded.

2.3. Assessment of Obesity Management Strategies {#sec2.3}
------------------------------------------------

Because each patient enrolled was deemed by the physician to require weight management, it was assumed that the physician would provide some counseling at the encounter. However, no prior instructions were given to standardize the weight management advice given. The focus of SOCCER was to identify whether or not at this visit the physician initiated or continued obesity pharmacotherapy for a given patient and whether or not the physician referred the patient for further weight management. If referral was made, the type of weight management strategy or strategies involved was recorded. The weight management strategies examined included dietary counseling, commercial weight loss program/popular diet, exercise program (e.g., a trainer or gym membership), behavioral therapy (e.g., psychologist), and bariatric surgery. Depending on the strategy, referral could take the form of explicit written communication to another provider (e.g., surgery) or simply consist of verbal instructions to the patient to seek a specific type of treatment (e.g., commercial weight loss program). In the case of bariatric surgery, data collection was limited to those individuals considered potentially eligible for surgery (BMI ≥ 35 kg/m^2^) \[[@B7]\].

Patients did not fill out any forms; forms were populated solely by physicians, and each physician was instructed to consider each weight management strategy in sequence and perform data entry in real time during the actual visit. For pharmacotherapy, physicians were asked to indicate if the patient will "start or continue pharmacotherapy TODAY". For the other weight management strategies, such as dietary counseling, instructions to the physician read as follows: "please indicate if you referred the patient for *Dietary Counseling* as a weight management strategy TODAY." Demographic information, employment status, medical history, physical examination, and current medications were also recorded at the time of the visit. In addition, physicians were asked to document if the reason for the referral was patient initiated and to provide the primary reason if referral was not made for a given strategy, choosing from the following categories (using check boxes): "patient refused", "not affordable", "not feasible", "past treatment failed", "contraindicated", and "not considered."

2.4. Predictors of Antiobesity Drug Use {#sec2.4}
---------------------------------------

An additional goal of SOCCER was to identify predictors of antiobesity drug use. Covariate-adjusted, binary logistic regression models were created to identify these predictors. Age, sex, BMI (per unit increase), ethnicity, type of practice (primary care versus specialist), supplemental health insurance, employment status (employed versus unemployed), gender concordance between patients and physicians (concordant versus discordant), and additional covariates that achieved a Wald Chi-square *P*-value significance level of  .1 univariately were also considered. The final model was created using a backwards selection method to determine which of these additional covariates contributed to the model at a Wald Chi-square *P*-value of  .1. Supplemental health insurance indicates the presences of private health coverage, which is primarily used to cover drug expenses. Sibutramine and orlistat are not covered by Canadian provincial health care plans and therefore patients typically pay out of pocket or through private insurance for these medications.

2.5. Data Collection and Statistical Analysis {#sec2.5}
---------------------------------------------

Paper-based case report forms were populated at point-of-care, faxed to the project management centre (Population Health Research Institute, McMaster University) and optically scanned using DataFax (Clinical DataFax Systems Inc., Hamilton, Ontario). The forms were reviewed for missing, illegible, or contradictory data input. All of the data management processes followed written standard operating procedures (SOPs) and conformed to Good Clinical Practice (GCP) standards for the conduct and data management of clinical studies.

Statistical analysis was performed using SAS, version 9.1 (SAS Institute, Cary, NC). For all statistical tests, two-tailed *P* values less than  .05 were considered statistically significant. Survey methods (PROC SURVEYLOGISTIC) account for the clustering of patients within individual physician practices \[[@B17]\]. With the exception of one practice that contained three physicians, only one physician per practice participated in the study. Furthermore, in the multi-physician practice, there were no differences in the use of pharmacotherapy or referral practices among the three physicians. Therefore, it was not necessary to control for physician clustering within practices.

2.6. Ethics Approval {#sec2.6}
--------------------

Ethics approval was obtained from both the Canadian Shield Research Ethics Board and the Research Ethics Board of McMaster University, Hamilton Health Sciences.

2.7. Funding {#sec2.7}
------------

SOCCER was funded by an unrestricted Grant from Abbott Laboratories Canada. The design, conduct and analysis of the study were carried out independently of the study sponsor.

3. Results {#sec3}
==========

3.1. Study Population and Comorbidities {#sec3.1}
---------------------------------------

Thirty-six physicians enrolled 1904 patients across 33 participating sites in 7 provinces. 108 (5.7%) did not have an indication for obesity management or meet age or BMI inclusion thresholds and were excluded. Eight patients were excluded because of missing BMI data, leaving 1788 patients included in the final analysis. Patients enrolled from specialty practices had higher mean BMI levels and greater comorbidity compared to patients seen in primary care practices ([Table 1](#tab1){ref-type="table"}). The most common comorbidities were hypertension (48%), dyslipidemia (43%), osteoarthritis (27%), back pain (29%), and type-2 diabetes (24%).

The percentage of patients with 0, 1, 2, 3, or \>3 comorbidities was 14.2%, 17.6%, 16.0%, 16.5%, and 35.7%, respectively.

3.2. Use of Pharmacotherapy and Referral for Other Obesity Management Strategies {#sec3.2}
--------------------------------------------------------------------------------

Pharmacotherapy was initiated or continued in only 21% of cases (39% were by patient request). The frequencies of referral for 0, 1, 2, or \>2 weight management strategies (including use of pharmacotherapy) were 29.0%, 22.8%, 26.2%, and 22.0%, respectively. Overall, referral was most common for exercise, in 49% of cases, followed by dietary advice, in 46% of cases. Only 5% of eligible patients were referred for bariatric surgery ([Table 2](#tab2){ref-type="table"}).

Predictors of initiating/continuing pharmacotherapy are summarized in [Table 3](#tab3){ref-type="table"}. In the multivariable adjusted model, male sex (OR 0.70; 95% CI 0.52--0.94) was associated with a lower likelihood whereas increasing BMI (1.02; 95% CI 1.01--1.03) and private drug coverage (1.78; 95% CI 1.39--2.29) were associated with a greater likelihood of initiating or continuing antiobesity drug therapy.

3.3. Reasons for Lack of Referral {#sec3.3}
---------------------------------

In all cases, physicians listed "not considered" as the main reason for not using pharmacotherapy (44% of cases) or not referring a patient additional weight management (32%--65% of cases and highest for bariatric surgery, [Table 2](#tab2){ref-type="table"}). The second most common reason overall for lack of referral was patient refusal and in the cases of referral for diet, exercise and behavioral therapy, "not feasible" was also cited as a reason in substantial minority of cases ([Table 2](#tab2){ref-type="table"}). "Past treatment failed", "not affordable", and "contraindicated" were cited in only a minority of cases.

4. Discussion {#sec4}
=============

In summary, in this study of 36 physicians seeing nearly 1800 patients specifically identified as requiring weight management, antiobesity pharmacotherapy was used in only 21% of cases. Furthermore, referral to additional weight management provider or programs was recommended less than 50% of the time. Physicians recorded "not considered" and "patient refused" as the primary reasons for not using these strategies.

The relatively low rates of use of pharmacotherapy or referral for additional weight management have been demonstrated in previous studies \[[@B8], [@B10]\], although three major differences in the design of SOCCER compared to previous studies are notable. First, only patients that, in the mind of the physician, unequivocally required weight management were enrolled. Second, physicians were instructed to record data in real time to avoid recall bias and were aware that they were being studied. Given these design factors, one perhaps might have expected the prevalence of drug therapy or use of additional weight management strategies to be higher than that observed. Third, SOCCER also focused on identifying the reasons for not using pharmacotherapy or referring patients, and it is clear that the decision not to proceed with these weight management strategies is related to both patient and physician decisions. Only in a minority of cases were these decisions based upon the presence of specific barriers such as cost. We also found that pharmacotherapy was more likely to be initiated or continued in women, heavier patients, and those with private drug coverage. This sex difference is consistent with previous studies (both from RCTs and population-based analyses of prescription fills) \[[@B13], [@B19]\]. Furthermore, no antiobesity drug is covered under a provincial drug plan in Canada; therefore, the drugs may be unaffordable to many who do not have private coverage.

One limitation of SOCCER is that followup probes examining why the physician failed to consider pharmacotherapy or referral or why the patient refused these actions were not performed. It is certainly possible that physicians may view such interventions as ineffective, may not be familiar with their availability, or may expect that the patient can be successful without further help. Physicians may be aware of data demonstrating poor long-term persistence rates with pharmacotherapy or may not view the benefit/risk ratio of current drugs to be favorable. A recent physician survey reported that physicians might have unrealistic expectations regarding how successfully patients can lose weight \[[@B10]\]. Weight losses of 38% were categorized as "a dream outcome", and 10% losses were viewed as "disappointing" despite data demonstrating that such relatively small amounts of weight loss can lead to clinically significant benefits including a reduction in the incidence of type 2 diabetes in high-risk patients \[[@B7], [@B20]\]. Conversely, patients may refuse help from healthcare providers because they are more confident that a self-directed weight management plan will be successful \[[@B21]\]. Patients may also not view a physician\'s office as appropriate venue for weight management and may instead seek alternate methods. In addition, barriers to weight management may limit uptake of weight management strategies. Many patient-related barriers have been identified, including a lack of motivation, failure to recognize obesity as a major health condition, time constraints, low socioeconomic status, intimate saboteurs, and comorbid health conditions (particularly psychological dysfunction and sleep disorders) \[[@B22]\].

Bariatric surgery was recommended in only 5% of eligible patients in SOCCER. Surgery is the only intervention that consistently leads to substantial weight reduction, and surgery also has been associated with reductions in mortality; improvements in quality of life, and has been shown to be cost effective at commonly cited thresholds. We theorize that physicians may simply fail to consider surgery as a viable treatment option or may be unaware of recent evidence demonstrating that surgery substantially reduces morbidity and mortality in severely obese patients \[[@B23]\]. Conversely, physicians may fail to consider surgery because of the absence of a surgical program in their vicinity or because of the extended (several years) wait times that exist in Canadian surgical programs, although one would have expected physicians to categorize this scenario as "not feasible" rather than "not considered" \[[@B24]\].

Because volunteer physicians practices (only 2% of the total number of practices contacted) within Canada were enrolled in SOCCER, results may be subject to selection bias and may not be generalizable to all physician practices within and outside this country. Compared to practices that were not interested in participating, practices volunteering to take part likely had higher levels of interest and expertise in weight management and may have been more likely to initiate weight management strategies. Because the study specifically entailed detailing antiobesity management strategies, participants may also have been more likely to use management strategies because they knew these were being measured (i.e., the Hawthorne effect \[[@B25]\]). Therefore, it is probable that the frequency of physician-initiated drug treatment or weight management referral was overestimated compared to "usual care" practices, and, therefore, our results may be considered conservative.

In conclusion, we have demonstrated in this analysis of Canadian physician practice patterns that rates of antiobesity drug use and referral for additional weight management strategies are low. In the majority of cases, either physicians fail to consider these management strategies or patients refuse them. If increased uptake of these guideline-concordant strategies is to be achieved, both patients and physician-related barriers to weight management will need to be examined and addressed.

This study was funded by an unrestricted Grant from Abbott Laboratories Canada. The sponsor had no role in the design, conduct, or analysis of the study. All authors contributed substantially to either the conception and design of the study or the data acquisition, analysis, and interpretation. R. P. wrote the initial draft of the paper with critical revision for important intellectual content provided by the other authors. R. P. had full access to the data and took responsibility for the integrity and accuracy of the data analysis. All authors approved the final version. R. P., A. S., and R. L. are supported by an alternative funding plan from the Government of Alberta and the University of Alberta. D. L. is supported by an alternative funding plan from the Government of Alberta and the University of Calgary.

###### 

Baseline Characteristics.

                                                        Overall *n* = 1788   Primary care *n* = 1300   Specialist *n* = 488   *P*-value for specialist versus primary care
  ----------------------------------------------------- -------------------- ------------------------- ---------------------- ----------------------------------------------
  Age, mean (SD), y                                     52.7 (14.3)          52.6 (14.6)               52.7 (13.6)            .94
  Weight, mean (SD), kg                                 100.6 (25.1)         95.8 (20.1)               113.6 (31.7)           \<.01
  BMI, mean (SD), kg/m^2^                               36.1 (7.9)           34.8 (6.3)                39.8 (10.2)            \<.01
  Male                                                  663 (37)             460 (35)                  203 (41)               .015
  Caucasian                                             1614 (90)            1153 (89)                 461 (95)               \<.01
  Employed                                              987 (55)             737 (57)                  250 (51)               .04
  Supplemental health insurance                         996 (56)             715 (55)                  281 (58)               .33
  Current smoker                                        245 (14)             189 (15)                  56 (12)                .09
  Gout                                                  75 (4)               45 (4)                    30 (6)                 .02
  Cancer                                                90 (5)               63 (5)                    27 (6)                 .56
  Polycystic ovarian syndrome                           43 (2)               24 (2)                    19 (4)                 .02
  Type 2 diabetes                                       436 (24)             239 (18)                  197 (40)               \<.01
  Impaired fasting glucose/impaired glucose tolerance   183 (10)             89 (7)                    94 (19)                \<.01
  Coronary artery disease                               166 (9)              79 (6)                    87 (18)                \<.01
  Congestive heart failure                              46 (3)               21 (2)                    25 (5)                 \<.01
  Peripheral arterial disease                           38 (2)               10 (1)                    28 (6)                 \<.01
  Stroke                                                49 (3)               34 (3)                    15 (3)                 .60
  Arrhythmia                                            73 (4)               45 (4)                    28 (6)                 .04
  Dyslipidemia                                          760 (43)             518 (40)                  242 (50)               \<.01
  Hypertension                                          853 (48)             582 (45)                  271 (56)               \<.01
  Depression                                            395 (22)             261 (20)                  134 (28)               \<.01
  Anxiety                                               284 (16)             213 (16)                  71 (15)                .34
  Eating Disorder                                       40 (2)               19 (2)                    21 (4)                 \<.01
  Osteoarthritis                                        478 (27)             289 (22)                  189 (39)               \<.01
  Back Pain                                             526 (29)             347 (27)                  179 (37)               \<.01
  Fibromyalgia/chronic fatigue                          88 (5)               69 (5)                    19 (4)                 .21
  Gall bladder disease                                  127 (7)              72 (6)                    55 (11)                \<.01
  Abnormal liver enzymes                                60 (3)               26 (2)                    34 (7)                 \<.01
  Gastrointestinal reflux                               357 (20)             249 (19)                  108 (22)               .16
  Incontinence                                          111 (6)              69 (5)                    42 (9)                 .01
  Sleep apnea                                           146 (8)              54 (4)                    92 (19)                \<.01
  Thrombosis/embolism                                   25 (1)               13 (1)                    12 (3)                 .03

Data are expressed as no. (%) unless otherwise noted.

SD: standard deviation; BMI: body mass index.

###### 

Frequency of use of pharmacotherapy or referral for antiobesity management expertise.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                       Pharmacotherapy used or referral recommended *n* (%)   Pharmacotherapy\            Reason not recommended *n* (%)                                                                              
                                                                                              not used or referral not\                                                                                                               
                                                                                              recommended *n* (%)                                                                                                                     
  ------------------------------------ ------------------------------------------------------ --------------------------- -------------------------------- ---------- ---------- --------- ---------- --------- ---------- ---------- ----------
  Pharmacotherapy                      375 (21)                                               146 (39)                    1413 (79)                        792 (56)   491 (35)   47 (3)    167 (12)   63 (5)    24 (2)     618 (44)   3 (0.02)

  Dietary counseling                   813 (46)                                               257 (32)                    974 (55)                         614 (63)   300 (31)   86 (9)    39 (4)     9 (1)     180 (19)   343 (35)   17 (2)

  Exercise training                    866 (49)                                               291 (34)                    920 (52)                         573 (62)   216 (24)   37 (4)    57 (6)     18 (2)    245 (27)   297 (32)   50 (5)

  Behavioral therapy                   277 (16)                                               49 (18)                     1508 (85)                        713 (47)   404 (27)   28 (2)    49 (3)     2 (0.1)   230 (15)   720 (48)   75 (5)

  Commercial programs/popular diets    261 (15)                                               97 (37)                     1527 (85)                        626 (41)   332 (22)   103 (7)   116 (8)    11 (1)    64 (4)     853 (56)   48 (3)

  Obesity surgery (BMI ≥ 35 kg/m^2^)   41 (5)                                                 24 (59)                     742 (95)                         227 (31)   134 (18)   4 (1)     16 (2)     12 (2)    61 (8)     482 (65)   33 (4)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Predictors of initiating pharmacotherapy.\*

  Variable                               Odds Ratio (95% CI)
  -------------------------------------- ---------------------
  Age                                    0.98 (0.97--0.99)
  Male                                   0.70 (0.40--1.23)
  Body mass index                        1.06 (1.03--1.08)
  Caucasian ethnicity                    1.52 (0.76--3.02)
  Specialist physician                   0.65 (0.21--2.0)
  Private drug coverage                  2.36 (1.52--3.66)
  Currently employed                     1.16 (0.82--1.66)
  Patient-physician gender concordance   0.71 (0.34--1.48)
  Current smoker                         1.61 (1.13--2.30)
  Gastroesophageal reflux disease        1.41 (0.97--2.05)

\*Multivariable final adjusted model.
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